Gynecological Oncology Unit, IRCCS CRO Centro di Riferimento Oncologico - National Cancer Institute, Aviano, Italy.
Woman's Health Sciences Department, Gynecologic Section, Polytechnic University of Marche, Ancona, Italy.
J Low Genit Tract Dis. 2020 Oct;24(4):381-386. doi: 10.1097/LGT.0000000000000567.
The aim of this survey was to evaluate the different surgical approaches for women with high-grade vaginal intraepithelial neoplasia (HG-VaIN) used in 8 hospitals in central and northern Italy in the last 20 years. In particular, the baseline characteristics of the patients and factors potentially leading to excisional treatment rather than ablation were considered. Moreover, the clinical outcome of patients treated for HG-VaIN (disease persistence or recurrence and progression toward invasive vaginal cancer) was analyzed.
The medical records of all women initially diagnosed with HG-VaIN and subsequently treated in 8 Italian hospitals from January 1996 to December 2016 were analyzed in a multicenter retrospective case series.
Among the 226 women included, 116 (51.3%) underwent ablative procedures and 110 underwent excisional surgery (48.7%). An ablative procedure was preferred in cases where multiple lesions were found on colposcopic examinations. Physicians decided more frequently to perform excisional procedures in women with menopausal status, high-grade referral cervical cytology, previous hysterectomy for human papillomavirus-related disease, or VaIN 3 on colposcopic-guided biopsy.
The surgical treatment of HG-VaIN should be tailored according to the clinical characteristics of each woman and each lesion. However, in potentially high-risk cases (VaIN 3, previous hysterectomy for human papillomavirus-related disease, and menopausal women) or in those cases in which an occult invasive disease cannot be ruled out, an excisional approach should be preferred.In any case, long-term follow-up is advisable in women treated for HG-VaIN.
本研究旨在评估意大利中部和北部 8 家医院在过去 20 年中治疗高级别阴道上皮内瘤变(HG-VaIN)的不同手术方法。本研究特别分析了患者的基线特征和可能导致选择切除治疗而非消融治疗的因素。此外,本研究还分析了接受 HG-VaIN 治疗(疾病持续存在或复发以及进展为侵袭性阴道癌)患者的临床结局。
本研究回顾性分析了 1996 年 1 月至 2016 年 12 月期间,8 家意大利医院最初诊断为 HG-VaIN 并随后接受治疗的所有女性患者的病历。
在纳入的 226 名患者中,116 名(51.3%)接受了消融治疗,110 名(48.7%)接受了切除手术。当阴道镜检查发现多个病变时,更倾向于选择消融治疗。对于绝经状态、高级别转诊宫颈细胞学检查、既往因 HPV 相关疾病行子宫切除术或阴道镜引导下活检发现 VaIN3 的患者,医生更倾向于选择切除治疗。
HG-VaIN 的手术治疗应根据每位患者和每个病变的临床特征进行个体化选择。然而,对于潜在高危病例(VaIN3、既往因 HPV 相关疾病行子宫切除术和绝经女性)或无法排除隐匿性浸润性疾病的病例,应选择切除治疗。无论如何,对于接受 HG-VaIN 治疗的女性,应进行长期随访。